Uncategorized
Alcon drug meets primary endpoint of change in BCVA for wet AMD
RTH258 met its primary endpoint of mean change in best corrected visual acuity from baseline to week 12 in a phase 2 study of patients with neovascular age-related macular degeneration, Alcon announced in a press release.RTH258, formerly known as ESBA 1008, is a novel, single-chain antibody fragment, which at a dose of 6 mg was compared with 2 mg Eylea (aflibercept, Regeneron) in a prospective, multicenter, randomized, double-masked study of 90 eyes.